Autophagic activation with Nimotuzumab enhances chemo-radiosensitivity

May 13, 2014

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone. Dr. Haizhu Song and co-workers from Jinling Hospital and the Medical School of Nanjing University in China demonstrated that nimotuzumab could enhance chemo-radiosensitivity by promoting autophagic cell death in esophageal squamous carcinoma (ESCC) cells.

Nimotuzumab is a humanized anti-EGFR monoclonal antibody that inhibits EGF-stimulated receptor autophosphorylation and downstream signaling pathways. The majority of prior investigations have focused on the therapeutic effects of nimotuzumab on cancer cells including cell cycle arrest and the induction of apoptotic cell death. Dr. Chen's laboratory detected the autophagic activity of ESCC cells following a combination of nimotuzumab with paclitaxel, cis-platinum or external beam radiation. These results showed that autophagic activation by nimotuzumab facilitated the antitumor effects of and irradiation in ESCC cells with high expression of EGFR. Therefore, nimotuzumab-combined therapy might be more beneficial for treating ESCC patients with a high level of EGFR expression and activation of autophagy; as part of a combined therapy or as an alternative approach to kill more efficiently.

"We hope that our study will be meaningful in gaining a mechanistic understanding of nimotuzumab-combined therapy and provide a potential strategy for improving therapeutic efficacy in esophageal squamous cell carcinoma," said Dr. Longbang Chen, corresponding author.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Song and colleagues provide evidence, worth pursuing, that activation of autophagy by nimotuzumab may provide increased chemosensitivity and radiosensivity in ESCC".

Explore further: EGFR protects cancer cells from starvation via a kinase-independent mechanism

Related Stories

A biotherapy strategy for esophageal cancer in the future

April 19, 2010

A research team from China focused on esophageal squamous cell carcinoma (ESCC) and characterized sphingosine 1-phosphate (S1P) receptor expression pattern and investigated the role of S1P receptors on ESCC cells proliferation ...

Useful biomarkers for esophageal squamous cell carcinoma

January 25, 2011

A research team from China investigated the expression profile of miRNA in esophageal squamous cell carcinoma (ESCC). They found that miRNAs were deregulated and miR-143 and miR-145 were downregulated in ESCC.

Recommended for you

Molecularly shutting down cancer cachexia

August 30, 2016

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Radiologists detect breast cancer in 'blink of an eye'

August 29, 2016

A new study by investigators at Brigham and Women's Hospital in collaboration with researchers at the University of York and Leeds in the UK and MD Andersen Cancer Center in Texas puts to the test anecdotes about experienced ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.